Q-omics provides the consensus-scored TMPRSS11B profile across patient tissues and cancer cell-line models. TMPRSS11B expression is associated with patient survival in 17 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, TMPRSS11B is differentially expressed in 4, with the highest sampling consensus in HNSC. Additionally, TMPRSS11B RNA expression shows 5,561 significant pathway-activity associations, with the highest sampling consensus in HNSC. Together, these results highlight HNSC as cancer lineages where TMPRSS11B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TMPRSS11B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TMPRSS11B survival associations across molecular data types. TMPRSS11B RNA expression shows survival associations in the most cancer types (17), followed by mutation status (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TMPRSS11B RNA expression–survival associations across cancer types. High TMPRSS11B expression shows unfavorable associations in DLBC, UVM, KIRC and LAML, but favorable associations in HNSC and LUSC. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for TMPRSS11B RNA expression.
This table summarizes TMPRSS11B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4, while mass-spec protein shows differences in 1. The strongest signals are observed in HNSC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for TMPRSS11B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TMPRSS11B shows lower tumor expression in HNSC and THCA and higher tumor expression in LUSC and LUAD. The HNSC box plot shows higher TMPRSS11B RNA expression in normal versus tumor tissue (log2 FC = −5.370, t-test p < 0.001).
This table shows molecular features associated with TMPRSS11B in patient tissues and cancer cell lines. In patient samples, TMPRSS11B shows the broadest associations at the RNA and protein expression levels, with HNSC recurring as the lineage with the largest associated feature set. In cancer cell lines, TMPRSS11B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in LIVER and LARGE_INTESTINE.
